Rigel Pharmaceuticals Inc RIGL
Rigel Pharmaceuticals Inc (Nasdaq: RIGL) is a hematology drug developer. Its lead program, R289, is in Phase 1 for relapsed/refractory lower-risk myelodysplastic syndromes. Its next catalyst on record is R289: ASH 2026 oral presentation with updated data from Phase 1b study including preliminary dose expansion efficacy (December 2026).
Upcoming catalysts
- December 2026R289 — ASH 2026 oral presentation with updated data from Phase 1b study including preliminary dose expansion efficacy
On November 4, 2026, we announced that we will present updated data from our ongoing Phase 1b study evaluating R289 in patients with R/R lower-risk MDS in an oral presentation at the upcoming 68th ASH Annual Meeting and Exposition taking place December 12-15, 2026
- December 2026R289 — Updated Phase 1b data for R289 in lower-risk MDS will be presented at the ASH Annual Meeting in December 2026.
Oral presentation at the ASH Annual Meeting in December will feature updated data from the ongoing Phase 1b study of R289 in patients with lower-risk MDS
Next further out: R289 — Recommended Phase 2 dose selection; completion of enrollment in Phase 1b study (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VEPPANU (vepdegestrant) | ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer | small molecule | Approved |
| GAVRETO (pralsetinib) | metastatic RET fusion-positive NSCLC; advanced/metastatic RET fusion-positive thyroid cancer | small molecule | Approved |
| REZLIDHIA (olutasidenib) | R/R AML with IDH1 mutation | small molecule | Approved |
| TAVALISSE (fostamatinib) | chronic ITP | small molecule | Approved |
| Olutasidenib (triplet) | mIDH1 AML (with decitabine and venetoclax) | small molecule | Phase 2 |
| Olutasidenib (monotherapy) | IDH1-mutated CCUS, lower-risk MDS, CMML | small molecule | Phase 2 |
| Olutasidenib (maintenance) | IDH1-mutated myeloid malignancies (post-transplant) | small molecule | Phase 2 |
| Olutasidenib (combination) | R/R IDH1-mutated myeloid malignancies with activated signaling mutations | small molecule | Phase 2 |
| Olutasidenib (TarGet-D) | newly-diagnosed IDH1-mutant high-grade glioma (with temozolomide) | small molecule | Phase 2 |
| R289 | relapsed/refractory lower-risk myelodysplastic syndromes | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.